GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.36.

A number of research analysts have weighed in on the stock. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Friday, August 9th. Morgan Stanley lifted their target price on shares of GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. Citigroup lowered their price target on GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. Finally, UBS Group lowered their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th.

GoodRx Stock Down 1.2 %

Shares of NASDAQ GDRX opened at $7.59 on Friday. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $2.85 billion, a PE ratio of -759.00, a P/E/G ratio of 3.55 and a beta of 1.38. The firm has a fifty day moving average of $8.02 and a 200-day moving average of $7.61. GoodRx has a 52-week low of $4.14 and a 52-week high of $9.26.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.02 earnings per share. On average, analysts anticipate that GoodRx will post 0.15 EPS for the current year.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.17% of the company’s stock.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in GoodRx during the 1st quarter worth approximately $1,638,000. Rubric Capital Management LP bought a new position in GoodRx during the fourth quarter worth $39,348,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in GoodRx by 61.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock worth $1,289,000 after purchasing an additional 68,835 shares during the last quarter. Jupiter Asset Management Ltd. acquired a new position in GoodRx in the first quarter worth $707,000. Finally, Liontrust Investment Partners LLP acquired a new stake in shares of GoodRx during the second quarter worth $520,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.